Chargement en cours...

Paroxysmal Nocturnal Hemoglobinuria Following Alemtuzumab Immunosuppressive Therapy for Myelodysplastic Syndrome and Complicated by Recurrent Life-Threatening Thrombosis Despite Anticoagulation: Successful Intervention with Eculizumab and Fondaparinux

The pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) is not fully understood. We report a patient with myelodysplastic syndrome who developed symptomatic PNH following treatment with alemtuzumab. A small PNH clone, identified prior to alemtuzumab, expanded resulting in hemolytic anemia and...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Cheng, Kit L., Brody, Judith, Warshall, Craig E., Sloand, Elaine M., Allen, Steven L.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2826546/
https://ncbi.nlm.nih.gov/pubmed/19836075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2009.09.024
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!